Literature DB >> 9279044

Selecting nursing home residents for satisfaction surveys.

S F Simmons1, J F Schnelle, G C Uman, A D Kulvicki, K O Lee, J G Ouslander.   

Abstract

Many cognitively impaired nursing home (NH) residents are excluded from interviews measuring quality of life or care based on the belief that these residents cannot accurately answer questions. These exclusions are based on subjective criteria and ignore individual differences among cognitively impaired NH residents. This study describes a screening rule based on four minimum data set (MDS) indicators that provides an objective method for identifying residents capable of accurate report. Sixty percent of a sample of 83 NH residents who could answer yes or no questions about their care could do so accurately. Eighty-one percent of the sample was correctly classified by the MDS indicators.

Entities:  

Mesh:

Year:  1997        PMID: 9279044     DOI: 10.1093/geront/37.4.543

Source DB:  PubMed          Journal:  Gerontologist        ISSN: 0016-9013


  4 in total

1.  Validating the accuracy of the resident satisfaction measure.

Authors:  Alice M L Chong
Journal:  J Cross Cult Gerontol       Date:  2003-09

Review 2.  Improving the quality of long-term care with better information.

Authors:  Vincent Mor
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

3.  Concordance of self- and informant-rated depressive symptoms in nursing home residents with Dementia: cross-sectional findings.

Authors:  Julie L O'Sullivan; Roxana Schweighart; Sonia Lech; Eva-Marie Kessler; Christina Tegeler; Andrea Teti; Johanna Nordheim; Paul Gellert
Journal:  BMC Psychiatry       Date:  2022-04-05       Impact factor: 3.630

4.  Resident-to-resident elder mistreatment (R-REM) intervention for direct care staff in assisted living residences: study protocol for a cluster randomized controlled trial.

Authors:  Jeanne A Teresi; Stephanie Silver; Mildred Ramirez; Jian Kong; Joseph P Eimicke; Gabriel D Boratgis; Rhoda Meador; Leslie Schultz; Mark S Lachs; Karl A Pillemer
Journal:  Trials       Date:  2020-08-12       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.